moderna and merck have achieved a major breakthrough with a phase 3 trial of their personalized mRNA cancer vaccine intismeran autogene, showing it significantly reduces melanoma recurrence when used with keytruda. this marks the first late-stage success for any mRNA cancer vaccine and has sparked optimism for a new era in oncology by harnessing personalized immunotherapy. the positive results drove stock surges for both companies and led to analyst upgrades, though questions remain about long-term growth and commercial rollout across other cancer types. discover what sets this innovative approach apart and its implications for biotech, investing, and cancer treatment worldwide
Read more